CN110573505B - C5-苯胺喹唑啉化合物及其在治疗癌症中的用途 - Google Patents

C5-苯胺喹唑啉化合物及其在治疗癌症中的用途 Download PDF

Info

Publication number
CN110573505B
CN110573505B CN201880027620.0A CN201880027620A CN110573505B CN 110573505 B CN110573505 B CN 110573505B CN 201880027620 A CN201880027620 A CN 201880027620A CN 110573505 B CN110573505 B CN 110573505B
Authority
CN
China
Prior art keywords
triazol
compound
amino
acetamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880027620.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110573505A (zh
Inventor
T.格雷库
J.G.凯特勒
M.J.帕克
S.E.皮尔逊
J.M.史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN110573505A publication Critical patent/CN110573505A/zh
Application granted granted Critical
Publication of CN110573505B publication Critical patent/CN110573505B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880027620.0A 2017-04-27 2018-04-26 C5-苯胺喹唑啉化合物及其在治疗癌症中的用途 Active CN110573505B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27
US62/490859 2017-04-27
PCT/EP2018/060798 WO2018197642A1 (en) 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
CN110573505A CN110573505A (zh) 2019-12-13
CN110573505B true CN110573505B (zh) 2023-04-11

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027620.0A Active CN110573505B (zh) 2017-04-27 2018-04-26 C5-苯胺喹唑啉化合物及其在治疗癌症中的用途

Country Status (13)

Country Link
US (2) US10273227B2 (https=)
EP (1) EP3615522B1 (https=)
JP (1) JP7128204B2 (https=)
KR (1) KR102603153B1 (https=)
CN (1) CN110573505B (https=)
AR (1) AR111494A1 (https=)
AU (1) AU2018259078B2 (https=)
CA (1) CA3059283A1 (https=)
ES (1) ES2888298T3 (https=)
MX (1) MX389244B (https=)
RU (1) RU2769694C2 (https=)
TW (1) TWI774758B (https=)
WO (1) WO2018197642A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7128204B2 (ja) * 2017-04-27 2022-08-30 アストラゼネカ・アクチエボラーグ Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
WO2022040341A1 (en) * 2020-08-20 2022-02-24 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
CN116782933A (zh) 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
KR20230066040A (ko) 2020-09-10 2023-05-12 젠맵 에이/에스 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
CA3189883A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
CA3190376A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
TW202345831A (zh) * 2021-12-09 2023-12-01 美商迪賽孚爾製藥有限公司 Ｋｉｔ激酶抑制劑及其使用方法
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
CN1835945A (zh) * 2003-06-17 2006-09-20 阿斯利康(瑞典)有限公司 作为Aurora激酶抑制剂的喹唑啉衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DK1382604T3 (da) 2001-04-27 2006-04-18 Kirin Brewery Quinolinderivater med en azolylgruppe og quinazolinderivater
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
AU2009246263B2 (en) 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
JP7128204B2 (ja) * 2017-04-27 2022-08-30 アストラゼネカ・アクチエボラーグ Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
WO2018197643A1 (en) 2017-04-27 2018-11-01 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
CN1835945A (zh) * 2003-06-17 2006-09-20 阿斯利康(瑞典)有限公司 作为Aurora激酶抑制剂的喹唑啉衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis, Antitumor Evaluation and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors;Guo-Wu Rao等;《ChemMedChem》;20130502;928-933 *

Also Published As

Publication number Publication date
CA3059283A1 (en) 2018-11-01
US20180312490A1 (en) 2018-11-01
MX389244B (es) 2025-03-20
BR112019022229A2 (pt) 2020-05-12
JP7128204B2 (ja) 2022-08-30
RU2019136279A (ru) 2021-05-27
RU2019136279A3 (https=) 2021-05-31
AR111494A1 (es) 2019-07-17
ES2888298T3 (es) 2022-01-03
AU2018259078A1 (en) 2019-10-17
JP2020517677A (ja) 2020-06-18
RU2769694C2 (ru) 2022-04-05
EP3615522A1 (en) 2020-03-04
TWI774758B (zh) 2022-08-21
EP3615522B1 (en) 2021-08-04
MX2019012847A (es) 2022-01-07
TW201904960A (zh) 2019-02-01
AU2018259078B2 (en) 2021-10-07
US20190263787A1 (en) 2019-08-29
US10273227B2 (en) 2019-04-30
WO2018197642A1 (en) 2018-11-01
US10829479B2 (en) 2020-11-10
KR20190141203A (ko) 2019-12-23
CN110573505A (zh) 2019-12-13
KR102603153B1 (ko) 2023-11-15

Similar Documents

Publication Publication Date Title
CN110573505B (zh) C5-苯胺喹唑啉化合物及其在治疗癌症中的用途
RU2656597C2 (ru) Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
AU2011311814B2 (en) Substituted pyridazine carboxamide compounds
CN116096710A (zh) 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
CN114364672A (zh) 苯并异噁唑磺酰胺衍生物
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
EA022087B1 (ru) Морфолинопиримидины и их применение в терапии
JP6139792B2 (ja) タンキラーゼ阻害剤としてのピリド［２，３−ｄ］ピリミジン−４−オン化合物
CN105377835A (zh) 酪氨酸蛋白激酶调节剂及其应用方法
JP7117323B2 (ja) フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
HK1188216B (en) Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant